Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Hims & Hers has risen 70% since November 2024, outperforming the S&P 500, despite recent regulatory challenges impacting its compounded semaglutide product. Its diversified portfolio in men's and ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

Hims & Hers Health stock plummeted after an FDA decision that prevents the company from selling compounded semaglutide. The company still expects to deliver strong revenue growth, though ...

Hims & Hers had previously offered compounded versions of semaglutide -- the GLP-1 drug marketed as Ozempic and Wegovy -- which it and other compounding pharmacies were allowed to do legally ...

Much of the excitement over Hims & Hers has been connected to the company's sales of compounded versions of GLP-1 inhibitor semaglutide. Novo Nordisk markets semaglutide as a treatment for type 2 ...